Pierre Fabre Medicament

Spain

All drugs from this manufacturer

  • BRAFTOVI 50 MG HARD CAPSULES

    It is used in adults to treat melanoma or non-small cell lung cancer (NSCLC) when they have a specific mutation in the BRAF gene and the cancer has spread or cannot be surgically removed. It is also used to treat colorectal cancer in adults with the same mutation who have already received other cancer treatments.

    Dosage form: capsules, hard

    Active substance Dosage
    encorafenib 50 mg

    ATC: L01E L01EC L01EC03

  • It is used in adults to treat melanoma or non-small cell lung cancer (NSCLC) when they present a specific mutation in the BRAF gene and the cancer has spread or cannot be operated on. It is also used to treat colorectal cancer in adults with the same mutation who have already received other cancer treatments.

    Dosage form: capsules, hard

    Active substance Dosage
    encorafenib Igual a 75 mg mg

    ATC: L01E L01EC L01EC03

  • It is used to treat hemangioma, which is a cluster of blood vessels in or under the skin. It is prescribed for children between 5 weeks and 5 months of age when lesions could endanger an organ or sense, when painful sores that do not heal are present, or when there is a risk of permanent scarring or disfigurement.

    Dosage form: solution, oral

    Active substance Dosage
    propranolol 3,75 mg

    ATC: C07A C07AA C07AA05

  • It is used to treat advanced or metastatic bladder and urinary tract cancer when previous treatments with platinum derivatives have not worked.

    Dosage form: solution for infusion, concentrate

    Active substance Dosage
    vinflunine 25 mg

    ATC: L01C L01CA L01CA05

  • It is used to treat advanced or metastatic bladder and urinary tract cancer when other treatments with platinum derivatives have not worked.

    Dosage form: solution for infusion, concentrate

    Active substance Dosage
    vinflunine 25 mg

    ATC: L01C L01CA L01CA05

  • It is used in adults to treat a type of skin cancer called melanoma or a type of lung cancer called non-small cell lung cancer (NSCLC), provided the cancer has a specific mutation in the BRAF gene and has spread to other parts of the body or cannot be removed by surgery.

    Dosage form: tablets, film-coated

    Active substance Dosage
    binimetinib 15 mg

    ATC: L01E L01EE L01EE03

  • It is used in adults to treat a type of skin cancer called melanoma or a type of lung cancer called non-small cell lung cancer (NSCLC), provided the cancer presents a specific mutation in the BRAF gene and has spread to other parts of the body or cannot be removed by surgery. It is taken together with another medication containing encorafenib.

    Dosage form: tablets, film-coated

    Active substance Dosage
    binimetinib 45 mg

    ATC: L01E L01EE L01EE03

  • It is used to treat patients with early-stage breast cancer who are hormone receptor-positive (HR-positive) and have HER2 overexpression or amplification (HER2-positive), and who have previously received treatment with trastuzumab less than one year ago.

    Dosage form: tablets, film-coated

    Active substance Dosage
    neratinib maleate 48,31 mg

    ATC: L01E L01EH L01EH02

  • It is used to treat the symptoms of an overactive bladder in adults, such as a sudden urge to empty the bladder (urgency), having to urinate more frequently than normal, or being unable to control urination and wetting oneself (urge incontinence).

    Dosage form: tablets, film-coated

    Active substance Dosage
    vibegron 75 mg

    ATC: G04B G04BD G04BD15